A5048105827- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Prostate Cancer Treatment and Research
- Lung Cancer Treatments and Mutations
- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Genetic factors in colorectal cancer
- Immunotherapy and Immune Responses
- Metastasis and carcinoma case studies
- Cancer, Hypoxia, and Metabolism
- Cancer Treatment and Pharmacology
- MicroRNA in disease regulation
- Radiopharmaceutical Chemistry and Applications
- Sarcoma Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Cancer Research and Treatments
- Glycosylation and Glycoproteins Research
- Bladder and Urothelial Cancer Treatments
- Monoclonal and Polyclonal Antibodies Research
- Cell Adhesion Molecules Research
- RNA modifications and cancer
Universität Hamburg
2016-2025
University Medical Center Hamburg-Eppendorf
2016-2025
Ludwig-Maximilians-Universität München
2009-2024
University Cancer Center Hamburg
2015-2024
German Cancer Research Center
2011-2024
Eppendorf (Belgium)
2008-2024
Eppendorf (Germany)
2003-2023
Elbe Kliniken Stade-Buxtehude
2022
Epilepsy Society
2022
Klinikum Wilhelmshaven
2020
We assessed the prognostic significance of presence micrometastasis in bone marrow at time diagnosis breast cancer by means a pooled analysis.
Abstract Purpose: The CellSearch system (Veridex, Warren, NJ) is designed to enrich and enumerate circulating tumor cells (CTCs) from peripheral blood. Here, we validated the analytic performance of this for clinical use in patients with metastatic breast cancer. Experimental Design: This prospective multicenter study conducted at three independent laboratories involved samples 92 Intra- inter-assay variability using controls containing defined numbers (average, 50 1,000, respectively), cell...
Cytokeratins are specific markers of epithelial cancer cells in bone marrow. We assessed the influence cytokeratin-positive micrometastases marrow on prognosis women with breast cancer.
Circulating tumor cells (CTCs) have been shown to predict reduced survival outcomes in metastatic breast cancer.CTCs were analyzed 2026 patients with early cancer before adjuvant chemotherapy and 1492 after using the CellSearch System. After immuno-magnetic enrichment for expressing epithelial-cell adhesion molecule, CTCs defined as nucleated cytokeratin lacking CD45. The followed a median of 35 months (range = 0-54). Kaplan-Meier analyses log-rank test used analyses. All statistical tests...
The development of monoclonal antibodies (MAbs) to cytokeratins, which are integral components the epithelial cytoskeleton, has made possible immunocytochemical detection tumor cells. Importantly, this technique allows cells that have metastasized from primary adenocarcinomas secondary sites such as bone marrow. aim study was not only detect micrometastatic in marrow, but also assess expression nuclear proliferation markers (Ki-67 and p120) erbB2 oncogene (also known ERBB2) these and, thus,...